Descovy® (emtricitabine/tenofovir alafenamide) – Expanded indication
September 29, 2017 – The FDA approved Gilead’s Descovy (emtricitabine/tenofovir alafenamide) tablets, in combination with other antiretroviral agents, for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and pediatric patients weighting at least 35 kg; and in combination with other antiretroviral agents other than protease inhibitors that require a CYP3A inhibitor, for the treatment of HIV-1 infection in pediatric patients weighting at least 25 kg and less than 35 kg.
Top